EZH2 and cancer: Compounds targeting these pathways may be active based on preclinical mechanistic cancer models and/or based on cancer patient data, including immune checkpoint blockade (anti-PD-1/PD-L1) and inhibitors of mTOR, PARP, ATR, EZH2, and HDAC (47, 48, 54, 84, 85).